#NICE #AZ #Lokelma #nephrology #AstraZeneca #hyperkalaemia #NHS #NICEcosteffectivenessthreshold #realworldevidence #reimbursement #NICEdraftguidance #persistenthyperkalaemia #chronickidneydisease #CKD #heartfailure #RAASinhibitors #RAASinhibitortherapies #TomKeithRoach #RWEdata
zurl.co/nl7Fy
zurl.co/nl7Fy
NICE update doubles eligible patients for AZ's Lokelma
AstraZeneca's hyperkalaemia drug Lokelma could see its use by the NHS more than double thanks to updated guidance from NICE.
pharmaphorum.com
April 14, 2026 at 8:42 AM